Zealand Pharma A/S (ZEAL): Price and Financial Metrics


Zealand Pharma A/S (ZEAL): $16.20

-1.93 (-10.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZEAL Stock Summary

  • Of note is the ratio of Zealand Pharma A's sales and general administrative expense to its total operating expenses; merely 0.47% of US stocks have a lower such ratio.
  • For ZEAL, its debt to operating expenses ratio is greater than that reported by only 0.52% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, Zealand Pharma A's debt growth rate surpasses only 0% of about US stocks.
  • Stocks that are quantitatively similar to ZEAL, based on their financial statements, market capitalization, and price volatility, are CGAU, LOV, BTEGF, CPG, and HTLD.
  • ZEAL's SEC filings can be seen here. And to visit Zealand Pharma A's official web site, go to www.zealandpharma.com.

ZEAL Stock Price Chart Interactive Chart >

Price chart for ZEAL

ZEAL Price/Volume Stats

Current price $16.20 52-week high $34.30
Prev. close $18.13 52-week low $9.93
Day low $15.55 Volume 4,798
Day high $16.45 Avg. volume 5,503
50-day MA $14.79 Dividend yield N/A
200-day MA $19.09 Market Cap 753.74M

Zealand Pharma A/S (ZEAL) Company Bio


Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company was founded in 1997 and is based in Copenhagen, Denmark.


ZEAL Latest News Stream


Event/Time News Detail
Loading, please wait...

ZEAL Latest Social Stream


Loading social stream, please wait...

View Full ZEAL Social Stream

Latest ZEAL News From Around the Web

Below are the latest news stories about Zealand Pharma A that investors may wish to consider to help them evaluate ZEAL as an investment opportunity.

Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022

Company announcement – No. 5 / 2022 Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022 Copenhagen, DK and Boston, MA, February 25, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Th

Yahoo | February 25, 2022

Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI)

Company announcement – No. 4 / 2022 Zealand Pharma Completes Enrollment in Phase 3 Trial of Dasiglucagon in Children with Congenital Hyperinsulinism (CHI) Top-line results expected in the second quarter of 2022Pending positive results, Zealand intends to file for marketing approval with the US Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. February 15, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and

Yahoo | February 15, 2022

Zealand (ZEAL) Ends Enrollment in Short Bowel Syndrome Study

Zealand Pharma (ZEAL) completes patient enrollment in the phase III EASE-SBS 1 study evaluating glepaglutide for the potential treatment of short bowel syndrome.

Yahoo | January 21, 2022

Needham Thinks Zealand Pharma’s Stock is Going to Recover

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Zealand Pharma (ZEAL – Research Report), with a price target of $42.00. The company's shares closed last Thursday at $21.18, close to its 52-week low of $19.33. According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -23.4% and a 19.8% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Apellis Pharmaceuticals, and Phathom Pharmaceuticals. Zealand Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $42.00, a 98.5% upside from current levels.

Catie Powers on TipRanks | January 20, 2022

Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Company announcement – No. 3 / 2022 Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending positive pivotal data, Zealand intends to file for marketing approval with the U.S. Food and Drug Administration Copenhagen, DK and Boston, MA, U.S. January 20, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the

Yahoo | January 20, 2022

Read More 'ZEAL' Stories Here

ZEAL Price Returns

1-mo 7.71%
3-mo 61.19%
6-mo -5.54%
1-year -39.84%
3-year -25.52%
5-year -9.45%
YTD -24.09%
2021 -40.62%
2020 8.25%
2019 185.96%
2018 -14.63%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4307 seconds.